John B Buse Selected Research

aleglitazar

1/2018	Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.
1/2018	Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.
4/2014	Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
9/2013	Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John B Buse Research Topics

Disease

171	Type 2 Diabetes Mellitus (MODY) 01/2024 - 07/2002
41	Hypoglycemia (Reactive Hypoglycemia) 01/2022 - 07/2009
38	Cardiovascular Diseases (Cardiovascular Disease) 01/2024 - 06/2008
31	Stroke (Strokes) 01/2024 - 11/2002
30	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 12/2023 - 07/2010
29	Myocardial Infarction 01/2024 - 11/2002
23	Heart Failure 11/2023 - 08/2003
21	Body Weight (Weight, Body) 01/2024 - 01/2007
19	Hyperglycemia 12/2021 - 01/2002
18	COVID-19 05/2024 - 01/2021
15	Weight Loss (Weight Reduction) 01/2023 - 11/2004
12	Chronic Renal Insufficiency 01/2023 - 11/2018
11	Nausea 01/2023 - 07/2009
9	Neoplasms (Cancer) 12/2023 - 07/2011
9	Dyslipidemias (Dyslipidemia) 01/2022 - 07/2002
8	Infections 03/2024 - 09/2018
8	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2022 - 09/2015
8	Weight Gain 01/2019 - 06/2009
7	Pancreatitis 01/2018 - 07/2011
6	Obesity 10/2023 - 03/2005
6	Diabetes Mellitus 11/2020 - 02/2003
6	Insulin Resistance 01/2018 - 06/2003
5	Peripheral Arterial Disease 01/2023 - 01/2018
5	Ketosis 01/2022 - 09/2015
5	Acute Coronary Syndrome 01/2020 - 09/2013
5	Unstable Angina 12/2019 - 04/2010
4	Post-Acute COVID-19 Syndrome 05/2024 - 12/2022
4	Diarrhea 01/2023 - 01/2011
4	Hypertension (High Blood Pressure) 01/2022 - 02/2013
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 04/2016
4	Vomiting 09/2015 - 01/2011
4	Inflammation (Inflammations) 09/2013 - 06/2011
3	Overweight 10/2023 - 03/2016
3	Kidney Diseases (Kidney Disease) 11/2022 - 01/2018
3	Albuminuria 01/2022 - 01/2021
3	Diabetes Complications 10/2019 - 06/2018
3	Glucose Intolerance 04/2010 - 01/2002
2	Coronary Artery Disease (Coronary Atherosclerosis) 01/2023 - 10/2021
2	Headache (Headaches) 01/2023 - 01/2011

Drug/Important Bio-Agent (IBA)

73	Insulin (Novolin)FDA Link 01/2023 - 06/2003
68	Glucose (Dextrose)FDA LinkGeneric 03/2024 - 01/2002
40	Liraglutide FDA Link 01/2022 - 07/2009
32	Metformin (Glucophage)FDA LinkGeneric 05/2024 - 01/2004
26	Insulin Glargine (Lantus)FDA Link 01/2022 - 06/2009
22	Exenatide (Byetta)FDA Link 01/2020 - 07/2003
18	Glucagon-Like Peptide-1 ReceptorIBA 03/2024 - 07/2009
18	omega-Chloroacetophenone (Mace)IBA 01/2024 - 07/2011
18	LipidsIBA 01/2020 - 01/2004
17	Blood Glucose (Blood Sugar)IBA 01/2024 - 07/2015
17	Glucagon-Like Peptide-1 Receptor AgonistsIBA 11/2023 - 01/2013
16	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2023 - 01/2007
16	Hypoglycemic Agents (Hypoglycemics)IBA 01/2023 - 07/2003
16	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2023 - 10/2008
15	semaglutideIBA 01/2023 - 01/2019
15	insulin degludecIBA 11/2021 - 11/2014
14	Sitagliptin Phosphate (Januvia)FDA Link 01/2022 - 07/2015
13	Sodium-Glucose Transporter 2 InhibitorsIBA 11/2022 - 07/2015
11	Sodium-Glucose Transport ProteinsIBA 01/2021 - 07/2015
9	SodiumIBA 03/2024 - 11/2018
8	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2021 - 07/2015
8	IncretinsIBA 01/2018 - 11/2004
7	Fluvoxamine (Luvox)FDA LinkGeneric 10/2023 - 01/2022
7	Ivermectin (Mectizan)FDA Link 10/2023 - 01/2022
7	Hemoglobins (Hemoglobin)IBA 11/2021 - 05/2009
7	Pioglitazone (Actos)FDA Link 01/2019 - 01/2004
6	(2S,3R,4R,5S,6R)- 2- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 6- (methylthio)tetrahydro- 2H- pyran- 3,4,5- triolIBA 01/2021 - 07/2015
6	CreatinineIBA 01/2021 - 01/2017
6	Fenofibrate (CiL)FDA LinkGeneric 01/2020 - 04/2010
6	Triglycerides (Triacylglycerol)IBA 01/2017 - 07/2002
5	Insulin Lispro (Humalog)FDA Link 01/2022 - 05/2009
5	ThiazolidinedionesIBA 11/2020 - 08/2003
5	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2020 - 08/2005
5	Fibric Acids (Fibrates)IBA 01/2020 - 06/2007
5	HDL CholesterolIBA 01/2017 - 07/2002
5	2,4-thiazolidinedione (thiazolidinedione)IBA 07/2011 - 01/2004
4	KetonesIBA 01/2021 - 09/2015
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020 - 06/2007
4	LDL CholesterolIBA 01/2020 - 11/2007
4	aleglitazarIBA 01/2018 - 09/2013
4	Rosiglitazone (Avandia)FDA Link 07/2009 - 01/2004
3	GlucokinaseIBA 01/2022 - 01/2019
3	TTP399IBA 01/2022 - 01/2019
3	Peptides (Polypeptides)IBA 04/2021 - 09/2009
3	SymportersIBA 11/2020 - 11/2018
3	AlbuminsIBA 01/2020 - 01/2020
3	Nonesterified Fatty Acids (NEFA)IBA 01/2018 - 07/2002
3	LDL Lipoproteins (beta Lipoproteins)IBA 01/2016 - 07/2002
3	IDegLiraIBA 10/2015 - 11/2014
3	Lipoproteins (Lipoprotein)IBA 08/2013 - 10/2007
3	Biomarkers (Surrogate Marker)IBA 07/2012 - 01/2007
3	1,5-anhydroglucitolIBA 06/2012 - 06/2006
2	Antiviral Agents (Antivirals)IBA 05/2024 - 06/2023
2	dulaglutideIBA 01/2024 - 01/2021

Therapy/Procedure

61	Therapeutics 03/2024 - 01/2004
36	Glycemic Control 01/2023 - 01/2004
9	Injections 01/2021 - 07/2010
6	Surgical Amputation (Amputations) 10/2021 - 11/2002
3	Subcutaneous Injections 01/2024 - 01/2017
2	Artificial Respiration (Mechanical Ventilation) 03/2024 - 11/2022
2	Drug Therapy (Chemotherapy) 12/2023 - 01/2002